BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 36901764)

  • 21. Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC.
    Moro M; Caiola E; Ganzinelli M; Zulato E; Rulli E; Marabese M; Centonze G; Busico A; Pastorino U; de Braud FG; Vernieri C; Simbolo M; Bria E; Scarpa A; Indraccolo S; Broggini M; Sozzi G; Garassino MC
    J Thorac Oncol; 2018 Nov; 13(11):1692-1704. PubMed ID: 30149143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inactivated Sendai virus induces apoptosis and autophagy via the PI3K/Akt/mTOR/p70S6K pathway in human non-small cell lung cancer cells.
    Zhang Q; Zhu H; Xu X; Li L; Tan H; Cai X
    Biochem Biophys Res Commun; 2015 Sep; 465(1):64-70. PubMed ID: 26235873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ganoderma microsporum immunomodulatory protein combined with KRAS
    Hua WJ; Hwang WL; Yeh H; Lin ZH; Hsu WH; Lin TY
    Int J Biol Macromol; 2024 Feb; 259(Pt 2):129291. PubMed ID: 38211909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER2 mediates clinical resistance to the KRAS
    Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S
    Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ma xing shi gan decoction eliminates PM2.5-induced lung injury by reducing pulmonary cell apoptosis through Akt/mTOR/p70S6K pathway in rats.
    Wang Y; Zhao B; Fei Y; Yin Q; Zhu J; Ren G; Wang B; Fang W; Li Y
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32627816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rosemary extract reduces Akt/mTOR/p70S6K activation and inhibits proliferation and survival of A549 human lung cancer cells.
    Moore J; Megaly M; MacNeil AJ; Klentrou P; Tsiani E
    Biomed Pharmacother; 2016 Oct; 83():725-732. PubMed ID: 27470574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).
    Parums DV
    Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Silencing the FOLR2 Gene Inhibits Cell Proliferation and Increases Apoptosis in the NCI-H1650 Non-Small Cell Lung Cancer Cell Line via Inhibition of AKT/Mammalian Target of Rapamycin (mTOR)/Ribosomal Protein S6 Kinase 1 (S6K1) Signaling.
    Xu X; Jiang J; Yao L; Ji B
    Med Sci Monit; 2018 Nov; 24():8064-8073. PubMed ID: 30415267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PI3K/Akt and mTOR/p70S6K pathways mediate neuroprotectin D1-induced retinal pigment epithelial cell survival during oxidative stress-induced apoptosis.
    Faghiri Z; Bazan NG
    Exp Eye Res; 2010 Jun; 90(6):718-25. PubMed ID: 20230819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Berberine represses human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK/mTOR/p70S6K and Akt signaling pathways.
    Zhang Q; Wang X; Cao S; Sun Y; He X; Jiang B; Yu Y; Duan J; Qiu F; Kang N
    Biomed Pharmacother; 2020 Aug; 128():110245. PubMed ID: 32454290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations.
    Strohbehn GW; Sankar K; Qin A; Kalemkerian GP
    Expert Opin Pharmacother; 2022 Oct; 23(14):1569-1575. PubMed ID: 36217844
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    An W; Zhang Y; Lai H; Zhang Y; Zhang H; Zhao G; Liu M; Li Y; Lin X; Cao S
    Oncol Rep; 2022 Aug; 48(2):. PubMed ID: 35730618
    [No Abstract]   [Full Text] [Related]  

  • 33. KRAS-targeted therapy in the treatment of non-small cell lung cancer.
    Yun J; Nakagawa R; Tham K
    J Oncol Pharm Pract; 2023 Mar; 29(2):422-430. PubMed ID: 35938195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS.
    Caiola E; Brunelli L; Marabese M; Broggini M; Lupi M; Pastorelli R
    Oncotarget; 2016 Aug; 7(32):51462-51472. PubMed ID: 27283493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Sotorasib treatment in KRAS G12C-mutated non-small cell lung cancer: Experience in the Tours university hospital].
    Bessy C; Blin T; Pichon E; Marchand-Adam S; Carmier D
    Rev Mal Respir; 2023 Jan; 40(1):17-23. PubMed ID: 36566134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib.
    Bauml JM; Li BT; Velcheti V; Govindan R; Curioni-Fontecedro A; Dooms C; Takahashi T; Duda AW; Odegaard JI; Cruz-Guilloty F; Jin L; Zhang Y; Anderson A; Skoulidis F
    Lung Cancer; 2022 Apr; 166():270-278. PubMed ID: 34838325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.
    Nakajima EC; Drezner N; Li X; Mishra-Kalyani PS; Liu Y; Zhao H; Bi Y; Liu J; Rahman A; Wearne E; Ojofeitimi I; Hotaki LT; Spillman D; Pazdur R; Beaver JA; Singh H
    Clin Cancer Res; 2022 Apr; 28(8):1482-1486. PubMed ID: 34903582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KRAS
    Hong DS; Fakih MG; Strickler JH; Desai J; Durm GA; Shapiro GI; Falchook GS; Price TJ; Sacher A; Denlinger CS; Bang YJ; Dy GK; Krauss JC; Kuboki Y; Kuo JC; Coveler AL; Park K; Kim TW; Barlesi F; Munster PN; Ramalingam SS; Burns TF; Meric-Bernstam F; Henary H; Ngang J; Ngarmchamnanrith G; Kim J; Houk BE; Canon J; Lipford JR; Friberg G; Lito P; Govindan R; Li BT
    N Engl J Med; 2020 Sep; 383(13):1207-1217. PubMed ID: 32955176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nootkatone, an AMPK activator derived from grapefruit, inhibits KRAS downstream pathway and sensitizes non-small-cell lung cancer A549 cells to adriamycin.
    Hung LVM; Moon JY; Ryu JY; Cho SK
    Phytomedicine; 2019 Oct; 63():153000. PubMed ID: 31280139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
    Reck M; Carbone DP; Garassino M; Barlesi F
    Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.